Moneyta · stock research · no sign-up needed
GILD
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$7.8B
+17.0% y/y
Net income (Q2 FY2026)
-$10.5B
as filed with the SEC
Institutions holding
2,289
-42 last quarter
Overview · GILEAD SCIENCES, INC.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease…
Management team
- Ms. Diane E. Wilfong · Interim Corporate Controller, Chief Accounting Officer & Principal Accounting OfficerFind on LinkedIn
- Ms. Johanna Mercier · Chief Commercial OfficerFind on LinkedIn
- Ms. Deborah H. Telman J.D. · Executive VP of Corporate Affairs, General Counsel & Corporate SecretaryFind on LinkedIn
- Mr. Andrew D. Dickinson · Chief Financial OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on GILD
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.